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Abstract
Hepatitis B virus (HBV) reactivation in rheumatoid 
arthritis (RA) patients undergoing biological therapy is 
not infrequent. This condition can occur in patients with 
chronic hepatitis B as well as in patients with resolved 
HBV infection. Current recommendations are mainly 
focused on prevention and management strategies 
of viral reactivation under tumor necrosis factor-α 
inhibitors or chimeric monoclonal antibody rituximab. In 
recent years, growing data concerning HBV reactivation 
in RA patients treated with newer biological drugs like 
tocilizumab and abatacept have cumulated. In this 
review, epidemiology, pathogenesis and natural history 
of HBV infection have been revised first, mainly focusing 
on the role that specific therapeutic targets of current 
biotechnological drugs play in HBV pathobiology; finally 
we have summarized current evidences from scientific 
literature, including either observational studies and 
case reports as well, concerning HBV reactivation under 
different classes of biological drugs in RA patients. 
Taking all these evidences into account, some practical 
guidelines for screening, vaccination, prophylaxis and 
treatment of HBV reactivation have been proposed.
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Core tip: Hepatitis B virus (HBV) infection represents a 
major issue in patients with rheumatoid arthritis (RA) 
undergoing biological disease-modifying anti-rheumatic 
drugs (bDMARDs). While several observational studies 
and trials deal with the risk of HBV reactivation under 
anti-TNF agents, there is limited experience with newer 
drugs as tocilizumab (TCZ) and abatacept (ABA). 
In this paper, literature concerning the risk of HBV 
reactivation in RA patients undergoing different classes 
of bDMARDs, including ABA and TCZ, has been revised. 
Finally, some evidence-based practical suggestions for 
the management of this condition are proposed.
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INTRODUCTION
Over the last decade, the introduction of biologic drugs 
for the treatment of rheumatoid arthritis (RA) led to 
significant improvements in clinical and radiographic 
disease outcomes. From available scientific evidences, 
low disease activity or even clinical remission 
resulted more frequently achievable with biologic and 
conventional synthetic disease-modifying antirheumatic 
drugs in combination (bDMARDs and csDMARDs, 
respectively) rather than with therapeutic regimens 
including csDMARDs only[1]. According to the current 
recommendations for RA management[2-6], bDMARDs 
may be initiated in patients who have failed to respond 
to at least one csDMARD, including methotrexate (if 
not contraindicated). Table 1 summarizes the principal 
bDMARDs currently licensed for RA treatment. The 
first generation of biological drugs targeting specific 
effector molecules in RA pathogenesis is represented 
by tumor necrosis factor alpha (TNF-α) inhibitors 
(TNFI). Five agents of such class of bDMARDs are 
currently approved for RA: three monoclonal antibodies 
[infliximab (IFX), adalimumab (ADA), and golimumab 
(GOL)], one modified antibody Fab fragment 
[certolizumab pegol (CZP)] and one soluble receptor 
[etanercept (ETN)]. Moreover, B-cell targeted therapy 
with rituximab (RTX), a chimeric monoclonal antibody 
against CD20, a B-lymphocyte antigen that specifically 
depletes mature B-cells, is another well-established 
therapeutic option for RA treatment. Recently other 
therapeutic agents targeting molecules involved in 
RA pathogenesis have been approved: tocilizumab 
(TCZ), a humanized monoclonal antibody against 
interleukin 6 (IL-6) receptor which selectively blocks 
IL-6 biological effects, and abatacept (ABA), a soluble 
CTLA4-Fc fusion protein, that, by mimicking the 
cytotoxic T-lymphocyte antigen 4 (CTLA4), a negative 
regulator of T-cell costimulation, mainly prevents 
the activation of the T-cell compartment. Either anti-
TNF, anti-IL-6 or costimulation blockade agents can 
be prescribed as first-line biologic therapies, while 
RTX is usually indicated as a second-line treatment 
option, that means for patients who failed and/or are 
intolerant to a first bDMARD, even if under certain 
circumstances, it can be considered as a first-line 
drug[4]. The combination therapy of a biologic agent 
with methotrexate (or another equivalent csDMARD 
such as leflunomide[7,8]) is generally more effective 
than monotherapy, as shown for TNFI[9], RTX[10] 
and TCZ[11]. Nevertheless, bDMARD monotherapy 
might be considered in case of contraindications for 
csDMARDs[12]. Biologic therapy is more effective than 
csDMARDs in achieving clinical response (measured 
by validated composite indexes) and in preventing 
radiographic damage as well. For instance, randomised 
controlled trials on TNFI show a remission rate of 50% 
vs 28% with ETN + methotrexate over methotrexate 
alone respectively[13]; similarly, ADA + methotrexate 
resulted in a remission rate of 34%, against 17% for 
methotrexate alone[14]. Furthermore, most evidences 
support the superiority of bDMARDs over csDMARDs 
in preventing structural and functional deterioration, 
even for long-term periods[14-17]. Compared to TNFI, 
newer bDMARDs, like TCZ and ABA, showed similar 
efficacy profiles, even if slight differences have been 
reported in specific contexts[18,19]. Despite their 
recognised therapeutic effects in most treated patients, 
biologic therapy with TNFI might result inadequate 
in approximately 30% of cases, thus carrying on the 
risk of further joint damage[20]. After TNFI failure, no 
particular bDMARD seems to be better than the others 
as second line choice[18-21]. 
All these drugs carry a potential for serious infective 
complications, especially involving the reactivation 
of latent infections with intracellular pathogens. This 
is particularly the case for latent tuberculosis, or 
latent infection with viruses such as Herpes Simplex 
Virus, hepatitis C and hepatitis B virus (HBV). The 
prevalence of HBV infection in patients affected by 
rheumatic diseases is similar to the one of the general 
population. In the last decade, increasing attention 
has been paid to the possibility of HBV reactivation 
in RA patients undergoing treatment with bDMARDs. 
Growing evidences, coming first from oncology, then 
from gastroenterology and rheumatology fields, 
suggest that HBV reactivation can occur not only in 
hepatitis B surface antigen (HBsAg) carriers, but also 
in HBsAg negative individuals presenting liver HBV-
DNA with detectable or undetectable serum HBV-DNA 
[occult HBV infection (OBI)], during or eventually after 
immunosuppression. Among the available bDMARDs 
approved for RA, the risk of HBV reactivation under 
TNFI has been well-described in several observational 
studies. Moreover, the evidences about the well-
established risk of HBV reactivation in hematological 
patients treated with RTX, have been replicated in 
several reports on RA patients. In contrast, for this 
topic, observational data for newer bDMARDs with 
different targets like ABA and TCZ are still lacking, 
with only a few reports published. Consequently the 
existing practical guidelines for the prevention and 
management of viral reactivation are mostly targeted 
to the “older” rather than to the newer bDMARDs. 
In this paper, literature concerning the risk of HBV 
reactivation in RA patients undergoing different classes 
of the most commonly prescribed bDMARDs has 
been revised. Finally, some evidence-based practical 
suggestions for the prevention and the treatment of 
this condition are proposed. 
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HBV: EPIDEMIOLOGY AND NATURAL 
HISTORY
Chronic infection with HBV is still a significant global 
health problem: about 2 billion people worldwide 
have been infected with HBV and approximately 
5% of the world population is affected with chronic 
HBV infection, which is the leading cause of HBV-
related complications such as chronic hepatitis, HBV-
related cirrhosis, and hepatocellular carcinoma (HCC), 
accounting for 500000 to 700000 deaths per year[22]. 
The geographic distribution of HBV infection can be 
described as follows: 88% of global population lives 
in areas of intermediate (HBsAg+ prevalence 2%-7%) 
or high endemicity (> 7%) corresponding to African 
and East-Asian territories where most infections occur 
from vertical transmission; whereas the remaining 
12% lives in low endemicity areas (HBsAg+ prevalence 
< 2%), roughly corresponding to North Europe 
and United States, where HBV infection usually 
primarily occurs in adulthood[23]. In western countries 
the incidence of HBV infection has been furtherly 
diminished by widespread vaccination programs since 
the 1980s[24]. HBV is a partially double-stranded DNA 
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  Class Mode of 
action
Drug Mechanism of action Route of 
administration
 Therapeutic regimen Half-life Major approved 
indications (FDA)
  TNF 
  inhibitors
TNF-α 
neutralization
Adalimumab 
(fully human 
monoclonal IgG1 
antibody)
Binding to TNF SC  40 mg every 2 wk 13 d RA, JIA, PsA, AS, 
CD, UC, PP, non 
radiographic axial 
SpA 
Golimumab 
(fully human 
monoclonal IgG1 
antibody)
Binding to soluble and 
membrane bound TNF
SC 50 mg every 4 wk 13 d RA, PsA, AS, UC
Certolizumab 
(pegilated 
FabI fragment 
of a human 
monoclonal 
antibody)
Binding to TNF SC 200 mg every 2 wk or 400 mg 
monthly 
14 d RA, CD, PsA, AS, 
non-radiographic 
axial SpA
Etanercept (p75 
TNF receptor - 
IgG1 Fc fusion 
protein
Works as a decoy 
receptor. It binds to 
soluble TNF, blocking 
the binding to its 
receptor
SC 50 mg weekly or 25 mg twice a 
week
3-6 d RA, PsA, AS, 
poliarticular JIA, PP
Infliximab 
(chimeric 
mouse-human 
monoclonal IgG1 
antibody)
Binding to soluble and 
membrane bound TNF
IV 3 mg/kg (up to 7.5 mg/kg if 
not effective) every 8 wk after 
loading at 0, 2 and 6 wk
9 d RA, PsA, AS, CD, 
pediatric CD, UC, 
pediatric UC, PP
  B-cell 
  depletion
B-cell lysis Rituximab 
(chimeric 
mouse-human 
monoclonal
IgG1 antibody)
Binding to CD20 and 
depletion
of CD20+ B cells
IV Two infusions of 1000 mg 2 wk 
apart. This can be repeated
every 6 mo if symptoms return. 
Infusions are
preceded by IV 
methylprednisolone to reduce 
the incidence of infusion 
reactions
18 d 
(range 5-76)
BNHL, CLL, RA, 
GPA, MPA
  T-cell   
  inhibition
T-cell 
costimulation 
blockade
Abatacept 
(extracellular 
domain of 
CTLA4-IgG1 
Fc recumbinant 
human fusion 
protein)
Binding to CD80/ 
CD86,
blocking T-cell co-
stimulation
IV 500-750-1000 mg infusions (for 
body weight < 60, between 
60 and 100 or > 100 kg) every 
4 wk following three loading 
infusions at 0, 2 and 4 wk 
13 d 
(range 8-25)
RA, poliarticular JIA
SC 125 mg weekly
  IL-6 
  inhibition
IL-6 receptor 
blockade
Tocilizumab 
(humanized 
monoclonal IgG1 
antibody)
Binding to soluble and 
membrane
bound IL-6 receptor
IV 8 mg/kg every 4 wk 10-13 d RA, poliarticular 
JIA, sistemic JIA
Table 1  Four classes of immunotherapies licensed to treat rheumatoid arthritis
FDA: Food and Drug Administration; CTLA-4: Cytotoxic T-lymphocyte associated-antigen 4; IL-6: Interleukin 6; IV: Intraveneous injection; PEG: 
Polyethylene glycol; SC: Subcutaneous; TNF: Tumour necrosis factor; JIA: Juvenile Idiopathic Arthritis; PsA: Psoriatic arthritis; AS: Ankylosing spondylitis; 
SpA: Spondiloarthritis; CD: Chron’s disease; UC: Ulcerative colitis; PP: Plaque psoriasis; BNHL: B-cell non-Hodgkin lymphoma; CLL: Chronic lymphocytic 
leukemia; GPA: Granulomatosis with polyangiitis (Wegener’s disease); MPA: Microscopic polyangiitis.
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Generally in these patients only anti-hepatitis B core 
antigen (anti-HBc) antibodies are detectable, because 
protective anti-HBs antibodies can be lost in time. The 
concept of occult HBV infection (OBI, defined with 
detectable liver HBV-DNA with serum undetectable 
or < 200 IU/mL HBV-DNA in HBsAg- individuals) has 
been recently introduced to describe the underlying 
risk of HBV reactivation under immunosuppressive 
therapy[29-31]. In this phase the risk of development 
of cirrhosis is minimal, whereas the risk of HCC is 
reduced but still significant[32]. Definitions of HBV 
status in virological, biochemical and serological terms 
are summarized in Table 2.
CURRENT MANAGEMENT OF CHRONIC 
HEPATITIS B 
Antiviral therapy is generally recommended for CHB 
patients who have HBV DNA levels > 2000 IU/mL, 
serum aminotransferases above the upper limit of 
normal (ULN) and moderate to severe active liver 
necroinflammation and/or at least moderate fibrosis[33]. 
Patients with alanine aminotransferase (ALT) > 2 times 
ULN and serum HBV-DNA > 20000 IU/mL may start 
treatment even without liver biopsy. The ideal end-
points of antiviral therapies are long-term suppression 
of viral replication, sustained HBeAg seroconversion 
for HBeAg+ individuals, and HBsAg clearance. Long-
term viral suppression can now be achieved in > 
95% cases with oral nucleic acid analogues (NAs), 
although HBsAg loss remains a hard to achieve 
target (< 10%). Drugs available for the treatment of 
CHB include interferon-α (IFN), pegylated-INF-α2a 
(PEG-IFN) and six NAs, that can be classified into 
nucleosides (lamivudine, telbivudine, emtricitabine, 
entecavir) and nucleotides (adefovir and tenofovir) 
analogues. While IFN-based regimens, despite a 
good efficacy profile, lead to frequent side effects and 
contraindications[33,34]; oral NAs show a better safety 
profile. Though inexpensive, the first generation agents 
(such as lamivudine) are associated with a high rate of 
viral resistance (about 70% after 5 years), which limit 
their use in clinical practice. Entecavir and tenofovir are 
virus transmitted by percutaneous or permucosal 
exposure to infected body fluids and perinatally from 
mother to infant. The virus genome is able to convert 
into a covalently closed circular form (cccDNA) that 
can persist lifelong into the nuclei of infected cells, 
leading to the likelihood of viral reactivation during or 
after immunosuppression[25]. 
Natural history of HBV infection is a dynamic 
process and runs throughout 4 distinct phases[26]. 
The immune tolerant phase is characterized 
by positive serum hepatitis B e antigen (HBeAg), 
serum HBV-DNA >105 copies/mL, and normal amino-
transferase levels. In this phase cellular response is 
absent, with consequent minimal liver inflammation. 
After vertical infection this phase may last > 40 years 
(possibly leading to HBV genome integration, with 
decreased likelihood of viral eradication), while it is 
usually short-term in adults.
The HBeAg-positive immunoactive phase is charac-
terized by a weak cellular response against infected 
hepatocytes, expressed by elevated aminotransferase 
levels (hepatitis), HBV DNA levels > 105 or between 
104-105 copies/mL, and histological evidence of 
liver inflammation. As serum viral load falls, HBe 
seroconversion (from HBeAg to anti-HBe) can occur at 
a rate of 4%-10% per year.
Most people after HBeAg seroconversion enter 
the so-called HBV inactive phase, associated with a 
more effective cytotoxic T-cell response leading to 
normalization of aminotransferases and undetectable 
or < 2000 UI/mL serum viral load (inactive carrier 
state). During this phase, which may last lifelong, 
liver inflammation improves along with a lower risk 
of serious complications. Nevertheless, an estimated 
20% of patients will reactivate, possibly leading to 
HBV-related complications: this condition, known as 
HBeAg-positive or HBeAg-negative chronic hepatitis 
B (CHB), is defined as HBsAg serum positivity for > 
6 mo, along with serum HBV-DNA between 2000 and 
20000 IU/mL or > 20000 IU/mL as well as elevated 
aminotransferases[26,27]. 
A proportion of patients develops HBsAg clearance 
at a rate of 0.5%-0.8% per year[28] (resolution phase). 
Table 2  Nomenclatures and definitions used in hepatitis B virus infection
  Markers Chronic inactive carrier HBeAg positive CHB HBeAg negative CHB “Resolved hepatitis B”
  HBsAg + + + -
  HBeAg - + - -
  Anti-HBe + - +/- +/-
  Anti-HBs + - +/- +/-
  Anti-HBc + +/- + +/-
  ALT - +/- + -
  Serum HBV-DNA Undetectable/< 2000 IU/mL Persistent/intermittent ↑ 
(> 20000 IU/mL)
Persistent/intermittent ↑ 
(> 2000 UI/mL)
 Detectable or undetectable
  Liver injury +/- Moderate/severe CHB Minimal to severe CHB -
  Necroinflammation No (> 90%) Yes (> 90%) No (> 90%) No
CHB: Chronic hepatitis B; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBe: Antibodies to hepatitis B e antigen; anti-HBs: 
Antibodies to hepatitis B surface antigen; anti-HBc: Antibodies to hepatitis B core antigen; ALT: Alanine aminotransferase.
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potent HBV inhibitors with a high barrier to resistance, 
and they are currently recommended as first-line 
monotherapies. These agents have to be given either 
indefinitely (HBeAg- CHB) or for 12 mo following 
HBeAg seroconversion in HBeAg+ CHB[35].
HBV REACTIVATION: DEFINITION AND 
RISK FACTORS
HBV reactivation in patients with chronic inactive/
resolved HBV infection undergoing immunosuppressive 
treatment is defined as the combination of two 
findings: a > 1 log10 IU/mL increase in serum HBV-
DNA level or the detection of previously undetectable 
HBV-DNA; and serum ALT elevation > 2-3 times the 
ULN[36,37]. The increase in liver function tests (hepatitis) 
usually follows viral reactivation[36]. Reactivation 
clinically ranges from a subclinical and transient event 
to severe hepatitis; in a limited proportion of patients 
acute liver failure and death have been reported, 
with a higher risk for patients affected by CHB and 
advanced histological injury[36].
The host serological status and HBV-DNA levels are 
major risk factors for HBV reactivation: HBsAg carriers 
are at greater risk, and the risk increases with HBV-
DNA load[36,37]. For HBsAg negative patients, the risk 
of reactivation is considerably lower in individuals with 
both anti-HBc and anti-HBs antibodies[38]. The risk may 
be higher in the event of concomitant methotrexate 
therapy[38]. A variety of immunosuppressive drugs may 
lead to HBV reactivation: corticosteroids, cytotoxic 
agents, cs- and bDMARDs. In most cases reactivation 
occurs after treatment withdrawal, as a result of 
the restored immunity[39]. The liver damage due to 
HBV reactivation is a two-stage process: initially 
during intense immunosuppression an enhanced viral 
replication occurs as reflected by increased serum 
and liver HBV-DNA; then, during the subsequent 
immune restoration after treatment withdrawal a 
rapid immune-mediated destruction of HBV-infected 
hepatocytes overcomes, clinically manifested with 
hepatitis, hepatic failure and even death. In a recent 
retrospective study of 35 cases of HBV reactivation in 
patients undergoing immunosuppressive treatment 
for immune-mediated inflammatory disease, reac-
tivation appeared a median of 35 wk (2-397) after 
treatment start, with earlier occurrence in RTX-treated 
and in HBsAg+/HBV-DNA+ patients[38]. However, earlier 
appearance was not associated with an increased 
clinical severity. Factors significantly associated with 
HBV-related serious complications (death and/or 
fulminant hepatitis) were identified in Asian ethnicity, 
delay from immunosuppressive therapy initiation 
to HBV reactivation diagnosis, HBV-DNA load and 
aminotransferases at HBV diagnosis. The use of 
specific TNFI/antiviral molecules did not differ between 
patient who experienced or not serious events, but 
patients with a poor outcome tended to receive IFX, 
ADA or 1st-generations NAs as compared with those 
with a favorable outcome (P = 0.07 and P = 0.03)[38].
ROLE OF PRO-INFLAMMATORY 
CYTOKINES IN HBV INFECTION
RA is a chronic inflammatory disease affecting 1% 
of adult population that predominantly involves the 
synovial membrane of diarthrodial joints. The disease 
is characterized by the activation of resident synovial 
macrophages in association with a massive synovial 
infiltration of lymphocytes and neutrophils, and by the 
local development of an inflammatory milieu, which 
in turn promotes the proliferation of synoviocytes and 
fibroblasts, and neoangiogenesis: all this leads to the 
production of an aberrant, hyperplastic tissue, the so-
called rheumatoid pannus, and to the differentiation 
and activation of chondrocytes and osteoclasts and 
subsequent cartilage and bone destruction. Apart from 
macrophages and other innate immunity “effector” cell 
types (dendritic cells, neutrophils, synoviocytes, osteo-
blasts, osteoclasts, and chondrocytes), three major 
pathways of RA immunity response have become 
recognized as pivotal: B-cells, T-cells, and a wide 
range of inflammatory cytokines that, acting as an 
intricate and redundant network both systemically and 
locally, shift the balance towards a proinflammatory 
state[40]. Synovitis is ultimately driven by a number 
of pro-inflammatory cytokines, such as TNF-α, IL-6 
and IL-1. TNF-α is overexpressed in the synovial fluid 
of patients with RA. Moreover, TNF-α transgenic mice 
spontaneously develop arthritis[41]. IL-6, a typical 
cytokine featuring redundancy and pleiotropic activity, 
also plays a key role in the development of RA[42], 
promoting an imbalance between Th17 and regulatory 
T (Treg) cells and the production of autoantibodies, 
such as rheumatoid factor (RF) and anticitrullinated 
peptide antibodies (ACPA). IL-6 also promotes synovial 
inflammation and cartilage and bone destruction and 
exerts systemic effects leading to cardiovascular, 
psychological, and skeletal disorders. 
RA was historically considered a T-cell driven 
disease, although adaptive humoral immunity also 
plays a pivotal role in its pathogenesis, as shown by 
the production of RF and ACPA, that are considered to 
be the serological hallmarks of RA. It has long been 
recognised that activated CD4 and CD8+ T-cell subsets, 
B-cells, plasmablasts and plasma cells are abundant 
in rheumatoid synovial tissue. A substantial proportion 
of patients show ectopic germinal centres that may 
support B cell maturation and class switching and 
thereby promote autoantibody production[43]. 
HBV infection causes acute and chronic necroin-
flammatory hepatitis. The pathogenesis of HBV 
infection, similarly to that of RA, is still largely un-
known. Massive hepatic injury occurring during CHB 
seems to be immune-mediated and depends on HBV-
specific cytotoxic T-cells[44]; moreover, an efficient 
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control of HBV infection requires the synergic actions 
of both innate and adaptive immunity[45]. 
Innate immunity induces in HBV infected cells 
the production of typeⅠinterferons and several 
proinflammatory cytokines, including TNF-α, IL-1, IL-6, 
and IL-10, some of which are reported to suppress 
viral replication and/or to exert non-cytolytic viral 
clearance. In HBV infected patients TNF-α is produced 
by intrahepatic leukocytes in a HBc-dependent 
fashion[46]. Several reports show intrahepatic and 
serum TNF-α elevation in patients with acute or 
chronic hepatitis B, suggesting a potential role in 
inhibiting viral replication[47]. The persistence of HBV 
infection may be associated with CD8+ T-cell loss of 
the ability to secrete enough TNF-α to kill infected 
hepatocytes (the so-called “exhausted phenotype’’)[48]. 
Genetic polymorphisms leading to lower TNF-α 
expression associate with an increased risk of HBV 
chronicization[49]. It has been recently demonstrated 
that in TNF-α knockout mice and in ETN-treated mice 
HBV infection persists, with subsequent increase in 
HBV-specific CD8+ T-cells, serum and liver HBV-DNA, 
and antigen expression. Thus in this animal model 
TNFI may be able to suppress HBc-dependent viral 
clearance effects[49]. However, in patients with CHB 
this cytokine may contribute to liver injury[50]. Other 
cytokines, like IL-1, might be involved in the natural 
history of HBV infection but data concerning their real 
role and meaning are still most elusive[51,52].
Cellular immunity is critical for the outcome of 
HBV infection, too: HBV-specific T-cells are involved 
in the control of viral infection, whilst non-specific 
NK cells infiltrate the liver leading to hepatocellular 
injury[53]. In humans, IL-6 in combination with TGF-β 
and IL-1β drive naive CD4+ T-cell to differentiate 
into Th17 cells in a HBc-dependent fashion[54]. Th17 
cells can produce multiple cytokines that trigger the 
recruitment and activation of neutrophils leading 
to massive tissue inflammation[55]. Recent reports 
showed that in CHB patients antigen non-specific 
Th17 response is increased and that the peripheral 
Th17 frequency is associated with the degree of 
liver damage[56,57]. A recent study revealed that the 
increased Th17 response in CHB patients correlates 
with the enhanced IL-6 receptor (IL-6R) expression 
on CD4+ T-cells, suggesting IL-6R as a potential novel 
target for CHB immunotherapy[58]. In addition, several 
studies demonstrated that IL-6 facilitates in vivo and 
in vitro HBV infection[59] and might be able to predict 
the development of HCC in HBV infected patients[60]. 
However, conclusive data are still lacking and the 
immunosuppressive action of the anti-IL-6R antibody 
TCZ might actually play a detrimental role.
CTLA-4, an inhibitory receptor expressed by 
activated T-cells that acts as a negative regulator 
of T-cell responses seems to be involved in HBV 
infection: studies in humans suggest an influence 
of CTLA4 polymorphisms in HBV clearance, HBV-
related carcinogenesis and HBV reactivation after 
immunosuppression, but the underlying mechanisms 
are still unclear[61-63]. 
Recent reports suggest that humoral immunity 
plays an important role in the immune response 
to HBV. HBcAg is able to directly activate B-cells 
to produce specific antibodies in the absence of 
regulatory T-cells[64]. In patients with HBeAg- CHB, 
CD20+ B-cells infiltrate the liver and correlate with 
histologic necroinflammation and fibrosis[65]. However, 
immunosuppression and B-cell suppression are asso-
ciated with viral reactivation. B-cells are thus involved 
in liver inflammation in HBV infected patients, but 
whether their influence on disease progression is 
harmful or beneficial is still unknown. 
SAFETY OF BMARDS IN PATIENTS WITH 
COMORBID HBV INFECTION
While in the last decade an amount of data has been 
cumulated regarding the effect of TNFI and RTX on RA 
patients with CHB or even OBI; the likelihood of HBV 
reactivation in patients undergoing newer bDMARDs 
TCZ and ABA has been more recently described. 
Available evidences stratified by bDMARDs about this 
topic will be exposed in the following sections. 
ANTI-TNF AGENTS 
It has been 11 years since the first reports of HBV 
reactivation after TNF-α blockade have been repor-
ted[66,67]; since then, a cumulative evidence from 
case reports and small retrospective or prospective 
studies has been collected[68-81]. TNFI-induced immu-
nosuppression is able to decrease HBV antigen 
presentation: the abrupt increase in viral presentation 
at treatment discontinuation induces an acute cyto-
toxic response, which can cause extremely severe 
hepatitis. Table 3 summarizes the observational studies 
of HBV reactivation in RA patients undergoing TNFI. 
A distinction has to be made between CHB patients 
(HBsAg+) and patients with resolved infection (HBsAg-/
anti-HBc+).
Patients with chronic HBV infection (HBsAg+)
In a 2011 review of 87 published cases of TNFI-treated 
CHB patients, Perez-Alvarez et al reported an HBV 
reactivation rate of 38%[76], similar to that observed 
under chemotherapy (50%)[36]. Half of the patients 
had received IFX, 33% ETN and 17% ADA. In most 
cases (about 75%), viral reactivation was accompanied 
by an increase in aminotransferase levels. Among 
patients with severe reactivation, 5 developed liver 
failure and 4 died from HBV-related complications. 
Interestingly, only 25% of the patients who developed 
HBV reactivation had received antiviral prophylaxis, 
compared to 62% of those who didn’t experience 
viral reactivation. Apart from potential publication 
bias, these data indicate an increased risk of HBV 
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not report any reactivation case in 50 TNFI-treated 
patients with resolved HBV infection and inflammatory 
arthritis[77]. Lee et al[79] have recently reported in a 
systematic review of 468 anti-HBc+/HBsAg- rheumatic 
patients undergoing TNFI a reactivation rate of 1.7%. 
Out of 8 cases, 7 were RA patients, and in all cases 
clinical outcome was satisfactory. In a japanese 
prospective study of 50 RA HBcAb+ patients treated 
with csDMARDs and/or TNFI, reactivation occurred in 
only 1 out of 45 HBsAg- patients (2.2%), treated with 
csDMARDs only. Interestingly, in TNFI-treated patients, 
anti-HBs titres decreased significantly in the middle- 
and low-titer groups (P = 0.032 and P = 0.007), 
remaining high in high-titer group (P = 0.875), but did 
not became negative in any patient[75]. It remains to be 
clarified whether a long period of TNFI therapy in RA 
patients induces the disappearance of anti-HBs leading 
to viral reactivation as well as in hematological field. 
A recent japanese retrospective study of 244 HBsAg-/
anti-HBc+ RA patients, HBV-DNA was detected in three 
patients (5.3%), only one receiving a TNFI, particularly 
ETN (out of a total of 48 TNFI-treated patients 
indicating a 2.1% reactivation rate). Reactivation 
consisted in a subclinical, transient HBV-DNA elevation, 
subsequently turning undetectable within months[81]. 
Even if limited by a possible publication bias, these 
data indicate that HBV reactivation in patients with 
serological markers of past HBV infection is a quite 
rare event and that for these patients no specific 
prophylaxis is required.
Vaccinated patients 
As suggested by a prospective study, a possible 
decrease in anti-HBs titer in TNFI-treated patients with 
remote HBV infection can occur[70], but this might not 
be systematically followed by viral reactivation such 
as in hematological field[85]. Similarly, in a prospective 
study of 19 HBV vaccinated patients a slight decrease 
in anti-HBs levels during TNFI treatment was repor-
ted[73], although a comparable decrease was observed 
in patients treated with methotrexate alone, indicating 
no specific effect of TNFI on HBV protective immunity.
RTX
A growing scientific literature indicates high rates 
of HBV reactivation in patients undergoing RTX for 
hematological diseases not receiving proper antiviral 
prophylaxis, ranging from 27% to 80% in HBsAg+ 
patients[39] and from 3% to 25% in HBsAg-/anti-HBc+ 
patients, with higher risk for anti-HBs- individuals[86,87]. 
Reports of HBV reactivation in rheumatic patients 
treated with RTX are summarized in Table 4. There are 
limited data regarding the safety of RTX in rheumatic 
CHB patients[68]; although, the efficacy of pre-emptive 
NAs (mainly lamivudine) in preventing reactivation in 
HBsAg+ patients treated with RTX appears to be similar 
to that observed in patients under chemotherapy, 
with a reactivation rate of 0%-13%[68]. Three recent 
reports from Southern Europe have described HBV 
reactivation in RA patients undergoing RTX, occurring 
not only in HBsAg carriers but also in two patients with 
resolved HBV infection. The first patient experienced 
HBV reactivation 1 mo after RTX administration, even 
though she had been receiving pre-emptive lamivudine 
for CHB. Lamivudine was thus switched to tenofovir 
with aminotransferases and HBV-DNA normalization[88]. 
In the second report, a RA patients with resolved 
HBV infection experienced HBV reactivation following 
2 years of therapy, 3 mo after the last RTX infusion. 
RTX was then withdrawn and entecavir initiated, with 
a gradual amelioration of aminotransferase levels and 
HBV-DNA normalization[89]. The third report involved a 
HBsAg-/anti-HBc+/HBV-DNA- RA patient that developed 
HBV reactivation with subsequent acute hepatitis after 
2 years of RTX + methotrexate combination therapy. 
Discontinuation of immunosuppressive treatment 
and antiviral therapy with entecavir resulted in the 
control of HBV infection within a few months[90]. A 
2013 prospective study did not report any case of 
HBV reactivation under RTX neither in a series of 2 
HBsAg+/HBV-DNA- rheumatic patients treated with 
antiviral prophylaxis nor in a series of 12 HBsAg-/
anti-HBc+ rheumatic patients, indicating a quite safe 
profile[91]. Interestingly, in the 4 patients with history 
of HBV vaccination, a slight decrease in antibody titers 
that did not reach statistical significance was noted. 
However, antibody titers did not fall below protective 
levels[92]. Droz et al[38] reported other 4 cases of 
HBV reactivation under RTX in patients affected with 
inflammatory diseases; indicating an earlier timing 
of viral reactivation for patient receiving anti-CD20 
treatment. 
NEWER BDMARDS
TCZ
There is limited experience with TCZ, a humanized 
anti-IL-6 receptor antibody, among HBV-infected RA 
patients (Table 5). Nagashima et al[92] reported that 
TCZ was administered safely and effectively in a RA 
patient affected with CHB, not recognised at baseline 
since serological screening for HBV had not been 
performed. In another case report, a patient with 
active RA stopped IFX due to HBV reactivation (pre-
treatment viral status unknown). She was then treated 
with lamivudine until HBV-DNA turned undetectable, 
and later started TCZ; this resulted in a prompt 
disease control together with persistently normal 
serum aminotransferases and undetectable HBV-
DNA[93]. A similar report regarding a CHB patient with 
adult-onset Still’s disease indicates an excellent disease 
control with no viral reactivation by introducing TCZ 
after complete viral control with entecavir[94]. A recent 
retrospective study from Nakamura et al described 2 
cases of HBV reactivation in RA patients undergoing 
TCZ without pre-emptive antivirals (out of a total of 
18 TCZ-treated HBsAg-/anti-HBc+ patients, with a 
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reactivation rate of 11.1%): in both patients HBV-
DNA rised but remained below quantitation limits (< 
2.1 log copies/mL), and then it spontaneously turned 
undetectable, along with normal aminotransferases 
throughout the entire period of follow-up: such data 
might suggest the possibility of a transient HBV-DNA 
fluctuation during the first 3-6 mo of TCZ, which 
doesn’t necessarily lead to de novo hepatitis and 
possibly resolves within a few months[81]. This evidence 
suggests that TCZ, if co-administred with pre-emptive 
NAs, could be a treatment option for RA HBV carrier 
patients when disease activity is uncontrolled with 
csDMARDs. However, periodic monitoring of liver 
function tests and HBV-DNA is mandatory. 
Abatacept
Studies regarding HBV reactivation in rheumatic 
patients undergoing ABA are summarized in Table 
6. A recent monocentric retrospective study has 
been performed including 8 ABA-treated RA patients 
showing active CHB (n = 2) or inactive HBsAg 
carriers (n = 6)[95]. All patients not receiving antiviral 
prophylaxis (n = 4), which were all inactive HBsAg 
carriers at baseline, experienced viral reactivation, 
with a > 10 fold increase of HBV-DNA. None of the 
NAs-treated patients (3 with entecavir and one with 
tenofovir) had viral reactivation. Moreover, patients 
who had been receiving both ABA and NAs showed 
a statistically significant improvement in DAS28 
compared to those without prophylaxis (P = 0.025). 
This is the first study suggesting that the use of 
ABA in RA/CHB patients appears to be safe and 
efficacious as long as pre-emptive antiviral prophylaxis 
is properly given. A case of severe hepatitis due to 
HBV reactivation has been reported in a RA patient 
with resolved HBV infection (HBV-DNA-) previously 
Table 4  Case reports and studies of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing rituximab
  Ref. Study design Patients 
charachteristics
Therapy Baseline 
virological 
status
Timing of HBV 
reactivation
Antiviral 
Therapy
Results Comments
  Pyrpasopoulou et al[88] Case Report 56-year-old female 
RA pt starting RTX 
after 3 anti-TNF 
(ETN, IFX, ADA) 
and ABA. Previous 
diagnosis of CHB
RTX
Antiviral 
prophylaxis 
with 
lamivudine
HBsAg+, anti-
HBe+
1 mo after 
first RTX 
administration
Tenofovir + 
lamivudine 
RTX 
withdrawal
Good clinical, 
serological 
and 
virological 
response
-
  Ghrénassia et al[89] Case Report 78-year-old with RA 
test+ and erosive 
RA starting RTX 
after IFX because 
of a concomitant 
diagnosis of 
lymphoma
RTX 
monotherapy
HBsAg-/anti-
HBc+
9 mo after RTX 
starts
Entecavir
RTX 
withdrawal
Good clinical, 
serological 
and 
virological 
response
-
  Gigi et al[90] Case Report 64-year-old female 
RA pt starting 
RTX as a first-line 
bDMARD
RTX + 
methotrexate
HBsAg-/anti-
HBc+
2 yr after RTX 
start
Entecavir
RTX 
withdrawal
Good clinical, 
serological 
and 
virological 
response
-
  Mitroulis et al[91] Prospective 
study
41 rheumatic pts 
(34 RA; 7 others) 
who had received 
≥ 1 cicle of RTX 
and had ≥ 6 mo of 
follow-up
17 pts 
treated with 
concomitant 
methotrexate, 
35 with 
concomitant 
steroids. 2 
pts treated 
with NAs 
without HBV 
reactivation
23 pts not 
HBV exposed; 
4 vaccinated 
pts; 12 
HBsAg-/anti-
HBc+ (9 anti-
HBs+); 2 pts 
HBsAg+ 
anti-HBc+. 
HBV-DNA 
undetectable 
in all pts
No cases of viral 
reactivation 
observed
- - Slight 
decrease in 
anti-HBs 
titres in 
vaccinated 
pts 
(P = 0.29), 
never under 
protective 
levels
  Droz et al[38] Retrospective 
(subgroup 
analysis)
4 pts affected with 
immune-mediated 
inflammatory 
disease treated with 
RTX
Not specified Not specified 4 cases of HBV 
reactivation a 
median of 35 
wk after therapy 
start (global 
data)
Not specified No cases of 
fulminant 
hepatitis
Early 
reactivation 
with RTX 
and in 
HBsAg+/
HBV-DNA+ 
pts (global 
data)
Pts: Patients; ETN: Etanercept; IFX: Infliximab; ADA: Adalimumab; ABA: Abatacept; CHB: Chronic hepatitis B; bDMARD: Biological disease-modifying 
antirheumatic drug; NAs: Nucleot(s)ide analogues; RTX: Rituximab;  HBsAg: Hepatitis B surface antigen.
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treated with a TNFI without antiviral prophylaxis and 
then with ABA, leflunomide and steroids. Nine month 
after the first ABA infusion, she experienced viral 
reactivation with liver function tests increase; this 
led to suspension of biological therapy. As expected, 
liver function tests continued to increase along with 
the gradual T-cell immune reconstitution, with a time 
lag of 2 mo between ABA withdrawal and viral flare. 
She was then treated with tenofovir with gradual 
amelioration of aminotransferases and undetectable 
HBV-DNA[96]. Another case of HBV reactivation in 
a RA patient with resolved HBV infection (basal 
HBV-DNA unknown) undergoing ABA was lately 
reported: 10 mo after treatment start, HBsAg turned 
positive along with a rise in HBV-DNA; treatment 
was then stopped and tenofovir was started, with 
a gradual amelioration of liver function tests and 
HBV-DNA within a few months[97]. In a recent italian 
case series of 9 RA patients treated with ABA (8 
with resolved HBV infection and 1 chronic inactive 
carriers), one patient with comorbid HCV chronic 
infection started lamivudine for liver function tests 
elevation (< 2-fold ULN) occurring 2 mo after ABA 
initiation, with a gradual amelioration of lab levels 
Table 5  Case reports of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab
  Ref. Study design Patient 
charachteristics
Therapy Basal virological 
Status
Timing 
of HBV 
reactivation
Antiviral 
Therapy
Results Comments
  Nagashima et al[92]  Case Report 60-year-old female 
RA pt, RA test and 
ACPA positive with 
erosive disease, 
starting TCZ after 
IFX and methotrexate 
TCZ + 
steroids
HBsAg-10 yr 
before TCZ start, 
basal serological 
screening not 
performed
6, 5 years 
after TCZ 
start
Entecavir
Ongoing 
TCZ
Subclinical, 
good serological 
and virological 
responses
Diagnosis made 
by detection 
of persistently 
high serological 
markers in an 
asymptomatic 
pt without liver 
function tests’ 
alterations
  Tsuboi et al[93]  Case Report 59-year-old female 
RA pt initially 
treated with IFX thus 
withdrawn for HBV 
reactivation
IFX and 
then TCZ 
(after HBV 
reactivation)
Serological 
screening not 
performed 
before IFX. At 
5th IFX infusion 
HBsAg+/HBV-
DNA+/HBeAg+
32 wk after 
IFX start
Lamivudine 
Ongoing 
TCZ
Good clinical, 
serological 
and virological 
response until 2 
years after TCZ 
start
-
  Kishida et al[94]  Case Report Adult-onset Still’s 
disease pt affected 
with CHB
TCZ + 
ongoing 
entecavir
HBsAg+ No 
reactivation 
observed
- Good clinical, 
serological 
and virological 
response until 
end of follow-up
-
  Nakamura et al[81]  Retrospective Among 9 RA pts 
treated with TCZ (7 
with TCZ alone and 
2 with TCZ and ABA 
in sequence), 2 cases 
of HBV reactivation 
were detected: 
(a) 75-year old male 
pt starting TCZ as a 
first line therapy
TCZ 
monotherapy
HBcAb+
Undetectable 
HBV-DNA
4 mo after 
TCZ start
- Subclinical, 
subserological, 
good virological 
response
HBV-DNA 
fluctuated always 
< 2, 1 log copies/
mL throughout 4 
mo until it became 
persistently 
undetectable, even 
after switch to 
ETN (due to lack 
of efficacy)
(b) 55-year-old female 
pt starting TCZ after 
IFX and ETN
TCZ + 
methotrexate
HBcAb+
Undetectable 
HBV-DNA
2 mo after 
TCZ start
- Subclinical, 
subserological, 
good virological 
response
HBV-DNA 
fluctuated always 
< 2, 1 log copies/
mL throughout 5 
mo until it became 
persistently 
undetectable, even 
after switch to 
ADA (due to lack 
of efficacy)
  Droz et al[38]  Retrospective 
(subgroup 
analysis)
1 pt affected with 
immune-mediated 
inflammatory disease 
treated with TCZ
Not specified Not specified median of 
35 wk after 
therapy 
start (global 
data)
Not 
specified
No cases of 
fulminant 
hepatitis
Early reactivation 
in HBsAg+/HBV-
DNA+ pts 
(global data)
Pts: Patients; ACPA: Anti-citrullinated peptide antibodies; IFX: Infliximab; CHB: Chronic hepatitis B; ABA: Abatacept; ETN: Etanercept; HBsAg: Hepatitis B 
surface antigen; TCZ: Tocilizumab; HCV: HCV: Hepatitis B virus.
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along with persistently undetectable viral load. Other 
2 patients (1 chronic inactive carrier and 1 with 
resolved infection) underwent lamivudine before ABA 
with no HBV-related adverse event, whilst among 
the other 6 HBsAg- patients not receiving antiviral 
prophylaxis only 1 developed HBV-DNA positivity 
(85 UI/mL) without aminotransferase elevation at 
12 mo[98], with subsequent fluctuations of viral load, 
turning initially negative at 18 mo and then rising again 
at 24 mo (290 UI/mL) without liver function tests 
alterations and without specific antiviral treatment. 
After infectivologist consult the patient thus started 
entecavir, concomitantly with switch to adalimumab for 
arthritis flare, with undetectable HBV-DNA 3 mo after 
TNFI start (unpublished data). 
CONCERNS ABOUT HBV VACCINATION
Hepatitis B vaccine (HBVv) is a recombinant DNA 
vaccine that provides protection against HBV infection 
and its complications, including cirrhosis and HCC[99]. 
As more than 1 billion doses of vaccine have been used 
 Table 6  Case reports of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing abatacept
  Ref. Study design Patients
characteristics
Therapy Basal 
virological 
status
Timing of HBV 
reactivation
Antiviral 
therapy
Results Comments
  Kim et al[95] Retrospective 8 RA pts 
affected with 
CHB
ABA + pre-
emptive NAs 
(4 pts: 3 with 
entecavir and 1 
with tenofovir)
ABA without 
antiviral 
prophylaxis 
(4 pts)
HBsAg+
Detectable 
HBV-DNA in 
3/8 pts
Not specified Not 
specified
Among pts 
receiving NAs, 
no cases of HBv 
reactivation. 
Among pts 
without antiviral 
prophylaxis, all 
pts experienced 
HBV reactivation
Among pts 
receiving NAs, 
a statistically 
significant 
improve in 
DAS28-ERS 
was detected; 
which was not 
noted in the 
control group
  Germanidis et al[96] Case Report 72-year-old 
female RA pt 
starting ABA 
after ADA
ABA + 
leflunomide
Anti-HBc+/
HBsAg-/anti-
HBs+/anti-
HBe+
6 mo after ABA 
start
ABA and 
leflunomide 
withdrawal
Consequent 
anviral 
treatment 
with 
tenofovir (12 
about 1 yr 
later)
Good clinical, 
serological 
and virological 
response to 
tenofovir
2 mo time lag 
between ABA 
withdrawal and 
liver tests flare, 
suggesting 
that HBV 
reactivation 
evolved in 
parallel with 
T cell immune 
reconstitution
  Fanouriakis et al[97] Case report 68-year-old 
female RA pt 
with erosive 
disease
ABA + 
methotrexate
HBsAg-/anti-
HBc+
Basal HBV-
DNA 
unknown
10 mo after ABA 
start
Tenofovir
ABA 
withdrawal
Good clinical, 
serological 
and virological 
response
-
  De Nard et al[98] Case series 9 RA pts treated 
with ABA
ABA
8/9 pts 
treated with 
concomitant 
methotrexate
Lamivudine in 
2 pts (1 HBsAg+ 
and 1 HBsAg-) 
from baseline, 
and in 1 pt with 
comorbid HCV 
infection after 
ABA start
8 HBsAg-/
anti-HBc+
1 HBsAg+/
HBV-DNA-
1 pt with comorbid 
HCV infection 
experienced 
aminotransferases 
elevation (< 2 x 
ULN) 2 mo after 
ABA start
Lamivudine
Ongoing 
ABA
Subclinical, 
gradual 
amelioration of 
liver function 
tests, persistently 
undetectable 
HBV-DNA
No cases 
of HBV 
reactivation 
among pts 
receiving pre-
emptive NAs
1 pt with resolved 
HBV infection not 
receiving NAs 
developed HBV-
DNA positivation 
12 mo after ABA 
start
Ongoing 
ABA
No 
prophylaxis
ConsecutiveHBV-
DNA fluctuations; 
no flares in liver 
function tests even 
after entecavir 
initiation at 24 mo 
while switching to 
ADA (unpublished 
data)
  Droz et al[38] Retrospective 
(subgroup 
analysis)
1 pt affected 
with immune-
mediated 
inflammatory 
disease treated 
with ABA
Not specified Not specified median of 35 wk 
after therapy start 
(global data)
Not 
specified
No cases of 
fulminant 
hepatitis (global 
data)
Early 
reactivation in 
HBsAg+/HBV-
DNA+ pts 
(global data)
Pts: Patients; CHB: Chronic hepatitis B; NAs: Nucleot(s)ide analogues; ADA: Adalimumab; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis B virus.
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since 1982, it is considered to be safe[100]. Vaccination 
scheme usually involves 3 booster injections and is 
currently indicated for high risk patients: newborns, 
health care workers and adults presenting conditions of 
immunosuppression or behavioral risk factors (multiple 
sexual partners, drug abusers, travelers to endemic 
areas)[100]. 
Some concerns have been raised on the possible 
development of autoimmune adverse events after 
HBVv: cases of multiple sclerosis, Guillain-Barre 
syndrome, idiopathic thrombocytopenic purpura, 
optic neuritis, glomerulonephritis, transverse myelitis, 
vasculitis, systemic lupus erythematosus diagnosis or 
flare-up[101,102] and even the so-called autoimmune/
inflammatory syndrome induced by adjuvants[103] 
have been reported[104]. Conflicting data about a 
possible association with HBVv and arthritis (RA or 
other) diagnosis or flare-up have been reported in 32 
cases and 3 controlled studies. In one study HBVv, 
compared to rubella vaccination, showed an increased 
risk of chronic arthritis incidence (attributable risk 
5.1-9.0)[105]; whilst two studies comparing the risk of 
RA flare following HBVv with RA controls[106] or with 
RA prevalence in the same community[104] did not 
find a significant association between HBVv and the 
risk of arthritis. Interestingly, in one of these studies 
a decreased efficacy of HBVv in RA patients was 
noticed[106]. These results do not provide solid scientific 
data to support the existence of a causal link between 
arthritis and HBVv: the most likely explanation 
still remains the coincidental temporal association. 
However, in a panorama of decreasing worldwide 
incidence of hepatitis B, mainly due to immunization 
programs, a recent “anti-vax” misconception is 
concentrating public attention and the media on 
vaccine adverse events rather than on prevention and 
control, which may lead to lower vaccine coverage and 
subsequent community wide outbreaks.
Routine vaccination before biotherapy initiation 
in patients with negative screening tests seems to 
be obviously appropriate; nevertheless, in patients 
affected with autoimmune diseases some precautions 
should be taken[78]: the risk of infection must be 
weighed against the theoretical risk of vaccine side 
effects, according to each patient’s profile (age, family 
history, risk factors, etc.)[107]. On the other hand, HBVv 
administration may delay biotherapy initiation, and the 
immune response may be blunted in patients affected 
with chronic arthritis taking immunosuppressants[107]: 
if we consider that a single injection is insufficient 
to induce protective immunization, if the following 
injections are administered under TNFI (most of all 
IFX and to a lesser degree ETN), they often fail to 
generate an immune response[108]. Since the risk of 
contracting HBV during adulthood is low, except for 
high-risk situation, HBVv might be postponed. In 
contrast, in high risk patients, particularly the younger 
ones, HBVv should be administered before treatment 
initiation[109]. In patients with resolved HBV infection 
and insufficient antibody protection (anti-HBc+/anti-
HBs-), a booster injection might be given to strengthen 
immunization[109] and to induce the production of 
protective anti-HBs, whose titer should be then 
measured.
RECOMMENDATIONS FOR CLINICAL 
MANAGEMENT OF RA PATIENTS WITH 
CHRONIC/RESOLVED HBV INFECTION 
UNDERGOING BDMARDS
Since proper prospective studies comparing different 
screening and treatment options for HBV-infected 
RA patients starting bDMARDs therapy are lacking, 
only expert-opinion-based suggestions can be 
made[2-4,6,33,38,68,82].
Screening
As stated by all the recent recommendations, all 
patients starting bDMARDs should be screened for HBV 
infection with HBsAg, anti-HBc and anti-HBs antibodies, 
as well as HBV-DNA load and liver function tests in 
patients found to be positive[2-4,6,68,82]. Considering the 
cost of chronic bDMARD therapy and the potential for 
serious HBV-related complications, such screening 
results to be cost-effective. Recent studies have shown 
that only 69% of US rheumatologists routinely performs 
universal HBV screening before biologic therapy[110]. 
When the results indicate active/remote HBV infection, 
a full battery of liver tests must be obtained, and it 
is appropriate to consult an hepatologist to evaluate 
whether antiviral treatment or prophylaxis is indicated 
before starting bDMARDs therapy[68].
Vaccination
As stated before, a careful risk-benefit assessment 
should be made concerning HBVv administration 
before bDMARD treatment. According to current 
recommendations[111], HBVv is only recommended 
in patients “at risk” (e.g., travel to or residence in 
endemic countries, medical profession, infected 
family member; only if protective antibodies against 
HBV are absent. Grade of evidence Ⅱ-Ⅲ; strength 
of recommendation B-D) and should ideally be 
administered during stable disease. Nevertheless, 
vaccination could also be considered in selected 
patients with active disease for whom the benefits of 
HBVv outweight the risks[99]. HBVv can be administered 
during the use of csDMARDs and TNFI but should 
ideally be administered before starting RTX (or, when 
treatment with RTX is already ongoing, at least 6 mo 
after the start but 4 wk before the next course[111]). 
Further studies are needed to establish indication and 
proper time of immunization in RA patients undergoing 
TCZ or ABA.
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Antiviral pre-emptive therapy and follow-up
Given the risk associated with IFN-based schemes 
in patients with autoimmune diseases, only NAs 
are recommended for these patients. To date, no 
consensus or recommendations are available regarding 
the specific bDMARD that should be preferentially 
chosen according to HBV infection profile. Pre-emptive 
treatment must be started (at least 1 mo) before 
the biotherapy, and must be prolonged (as well as 
virological monitoring) until at least 6 mo after its 
discontinuation. The efficacy of pre-emptive lamivudine 
has been retrospectively assessed in 88 RA patients 
treated with TNFI showing markers of recent/remote 
HBV infection[77]: for HBsAg+ patients, 5 of 8 untreated 
patients underwent HBV reactivation versus none of 
10 treated patients. Regarding the 70 HBsAg-/anti-
HBc+ patients, without antiviral prophylaxis, a single 
case of HBV reactivation was reported in a patient with 
OBI (HBV-DNA+, anti-HBs-). Nevertheless, newer NAs 
such as entecavir and tenofovir are considered the first 
choice for patients at high risk of HBV reactivation, due 
to lower risk of drug resistance. However, comparative 
data between lamivudine and newer NAs for pre-
emptive therapy of HBV reactivation are lacking. In 
addition, the potential side effects of entecavir and 
tenofovir must be weighed against the excellent safety 
profile of lamivudine. The current recommendations 
are summarized below.
For HBsAg+ patients, antiviral therapy should be 
initiated before any bDMARDs therapy[68]. The choice 
of the appropriate NA mainly depends on the duration 
of the scheduled therapy and on HBV serology status 
(CHB vs inactive carrier). In general, patients receiving 
long-term immunosuppression (> 12 mo) and/or 
suffering from CHB are placed on the newer NAs[34]. 
For patients with HBV-DNA < 2.000 IU/mL who are 
scheduled for short-term immunosuppression (< 12 
mo) treatment with lamivudine should be considered. 
Biotherapy should not be started until the HBV-
DNA levels become undetectable, and thus frequent 
(after 1 mo, then every 3-6 mo) monitoring of HBV-
DNA and liver function tests is mandatory[35,81]. This 
recommendation might safely be applied to patients 
undergoing TCZ and ABA.
For HBsAg-/anti-HBc+ patients undergoing bD-
MARDs, additional risk factors should be taken into 
account: HBV-DNA positivity, presence of anti-HBs 
(which should protect against reactivation, although 
this effect is controvertial, mostly with RTX), and the 
degree of immunosuppression induced by different 
bDMARDs, particularly for RTX. Baseline screening 
for HBV-DNA is always recommended, and if found 
to be positive, it is appropriate to start newer NAs[34]. 
In patients with resolved HBV infection (undetectable 
HBV-DNA) undergoing TNFI, simple monitoring 
without pre-emptive treatment is recommended 
(particularly if also anti-HBs+): liver function tests, 
HBsAg and HBV-DNA should be assessed 1 mo 
after treatment start, and then every 3-6 mo. Pre-
emptive treatment should also be strongly considered, 
regardless of HBV-DNA status, for patients undergoing 
RTX. Moreover, although there are few data concerning 
newer bDMARDs, we suggest that also for ABA-treated 
patients, regardless of HBV-DNA status, antiviral 
prophylaxis should be taken into account; whilst TCZ 
is relatively safe. In these cases, regular monitoring 
of aminotransferases, HBsAg and/or HBV-DNA every 
3-6 mo of follow-up is mandatory. 
When HBV reactivation is diagnosed, as soon as 
HBV-DNA becomes detectable and before hepato-
cellular damage starts, antiviral therapy must be 
promptly initiated and immunosuppressive therapy 
must be discontinued. If HBV-DNA becomes positive 
during lamivudine therapy, the patient should be 
switched to tenofovir, since cross-resistance has been 
reported between lamivudine and entecavir. 
CONCLUSION
HBV infection is a relevant worldwide condition, 
affecting also rheumatologic patients. Immuno-
suppressive treatment with bDMARDs might interfere 
with HBV natural history, leading to an increasing 
risk of viral reactivation, with consequent liver 
damage, up to possible fulminant hepatitis and death. 
Rheumatologists should be well-aware about such 
risk in RA patients undergoing different classes of 
bDMARDs, in order to define drug by drug proper 
preventive and therapeutic strategies. More robust 
evidences about newer bDMARDs (TCZ and ABA) 
are still needed in order to better define their specific 
drug-related risk in HBV infected RA patients and 
to draw univocal recommendations. An integrated 
management of this subset of patients should be 
encouraged between rheumatologists and virologists. 
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